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Abstract
Central line-associated bloodstream infection (CLABSI) event data reported to the National 
Healthcare Safety Network from 2014, the first year of required use of the mucosal barrier injury 
laboratory-confirmed bloodstream infection (MBI-LCBI) definition, were analyzed to assess the 
impact of removing MBI-LCBI events from CLABSI rates. CLABSI rates decreased significantly 
in some location types after removing MBI-LCBI events, and MBI-LCBI events will be removed 
from publicly reported CLABSI rates.
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Introduction
In 2013, the National Healthcare Safety Network (NHSN) introduced the mucosal barrier 
injury laboratory confirmed bloodstream infection (MBI-LCBI) definition in the NHSN 
protocol for surveillance of bloodstream infections. The MBI LCBI definition was 
developed to enable surveillance staff in hospitals to identify and report bloodstream 
infections in oncology patients that likely were the result of mucosal barrier injury and 
therefore not preventable through recommended central line insertion and maintenance 
practices [1]. Analysis of the first year of MBI-LCBI data reported to NHSN suggested that 
excluding MBI-LCBI events from central line-associated bloodstream infection (CLABSI) 
rates would result in large (>40%) overall reductions in CLABSI rates from inpatient 
oncology locations but would only reduce CLABSI rates modestly nationwide [2]. However, 
reporting whether CLABSIs fulfilled the MBI-LCBI criteria during 2013 was an optional 
part of the CLABSI protocol [2]. Whether required reporting of MBI-LCBI would result in a 
different impact on overall CLABSI rates was unclear. Here, we describe the epidemiology 
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of MBI-LCBI events reported to NHSN in 2014, the first year that identification of MBI-
LCBI events was required by the NHSN CLABSI protocol.
Methods
We analyzed all 2014 CLABSI data reported to NHSN from inpatient locations in short-term 
acute care hospitals. Other hospital types were excluded because few or no MBI-LCBI 
events were reported. Inpatient location types (e.g., adult and pediatric ward and critical 
care, adult and pediatric oncology ward and critical care) were designated by the reporting 
hospitals [3]. Definitions of CLABSI and MBI-LCBI can be found in the NHSN CLABSI 
protocol [4]. We described hospital and location types reporting MBI-LCBI events. For 
simplicity all location types not specified as pediatric are referred to here as “adult.” Pooled 
mean CLABSI rates per 1000 central line-days were calculated as (number of CLABSI) × 
1000 / (number of central line-days), both including and excluding MBI-LCBI events. 
Pooled mean rates for 2014 were stratified by inpatient location type. All analyses were 
performed with SAS 9.3 (SAS Institute, Cary, North Carolina, USA).
Results
CLABSI data were reported from 16,755 inpatient locations from 3,293 hospitals in 2014. 
The most common hospital types were general (95.4%) and children’s (2.3%), and the most 
common location types were adult ward (47.3%), adult critical care (30.5%), and neonatal 
intensive care (6.0%).
During 20,691,116 central line days of surveillance, these hospitals and inpatient locations 
reported 19,130 CLABSI of which 2017 (10.5%, 95% confidence interval [CI], 9.3–11.8%) 
were reported as MBI-LCBI events (Table). The majority of MBI-LCBI events were 
reported from general hospitals (71.0%), oncology hospitals (15.3%), and children’s 
hospitals (13.2%). The largest number of MBI-LCBI events were reported from adult 
oncology (1172 [58.1% of all MBI-LCBI]) and pediatric oncology (327 [16.2%]) ward 
locations. In addition, among non-oncology locations, the proportion of CLABSI that were 
MBI-LCBI was greater in pediatric critical care and ward locations (4.1% and 11.9%, 
respectively) than in adult critical care and ward locations (1.9% and 5.1%, respectively).
Excluding MBI-LCBI events from CLABSI rates resulted in the greatest reductions in 
pooled mean CLABSI rates in pediatric oncology ward (48.2% reduction, 95% CI, 43.9–
51.8%), adult oncology ward (45.8%, 95% CI, 43.6–47.8%), and adult oncology critical care 
locations (29.8%, 95% CI, 5.2–44.3%) (Table). Reductions in pooled mean CLABSI rates 
were smaller among non-oncology locations, including pediatric ward (11.9% reduction, 
95% CI, 1.5–20.3%), adult ward (5.1%, 95% CI, 2.3–7.8%), and adult critical care locations 
(1.9%, 95% confidence interval, −0.4–4.0%). The CLABSI rate including MBI-LCBI was 
1.8/1000 central line days for adult oncology wards; when MBI-LCBI events were excluded, 
the rate dropped to 1.0/1000 central line days. In contrast, in adult non-oncology wards, 
exclusion of MBI-LCBI events had no impact on the CLABSI rate, which was 0.7/1000 
central line days with and without MBI-LCBI events.
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Quantification of the impact of removing MBI-LCBIs from CLABSI data is necessary to 
enable accurate interpretation of CLABSI trends over time, and inform changes to state and 
federal reporting programs. This examination of data from the first year of required MBI-
LCBI reporting in NHSN found that overall approximately 1 in 10 (10.5%) CLABSI met the 
MBI-LCBI definition. Most MBI-LCBI were reported from oncology locations, and 
pediatric locations (both ward and critical care) had a higher proportion of CLABSI that 
were MBI-LCBI events compared to their adult counterparts. Importantly, our findings show 
the exclusion of MBI-LCBI events from the calculation of CLABSI rates primarily reduced 
the pooled mean CLABSI rates in oncology locations; by ~30% (in adults critical care 
oncology) and up to 48% (in pediatric oncology wards). Excluding MBI-LCBI events 
reduced differences between CLABSI rates in these oncology location types and the 
corresponding non-oncology locations. Although in pediatric oncology critical care 
locations reductions in CLABSI rates appear to be more modest, few events overall were 
reported in this location type making comparisons limited. These findings are largely 
consistent with what was seen from optional CLABSI reporting [2]. This analysis does not 
directly address potential differences in patient mix among a single NHSN location type, 
though the MBI-LCBI definition is likely to be of benefit when such differences are related 
to the presence of oncology patients in some locations and not others.
CDC is using 2015 NHSN data to update models used for risk adjustment of healthcare-
associated infection rates, including CLABSI. MBI-LCBI events will be excluded from 
publicly reported CLABSI rates in the updated models beginning with 2015 data. This 
change should bolster efforts to identify locations or facilities where improvements in 
central line care are most needed for CLABSI prevention [5,6]. In addition, although the 
MBI-LCBI definition was developed to enable identification of BSIs that may not be related 
to central line care and maintenance, MBI-LCBI events in themselves are important targets 
for prevention as they also represent significant healthcare-related adverse events. The 
development of the MBI-LCBI definition and the subsequent refinement of the CLABSI 
definition highlight NHSN’s commitment to ensuring the utility of its data for directing 
prevention needs locally and guiding public policy decisions.
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